Your browser doesn't support javascript.
loading
Efficacy of pentoxifylline for the treatment of bipolar I/II patients with treatment-resistant depression: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
Mohammad, Tavgah Ahmed Merza; Mohammad, Talar Ahmed Merza; Shawis, Teshk Nouri.
Afiliación
  • Mohammad TAM; University of Sulaimani, College of Nursing, Department of Community Health Nursing, Sulaimani, Kurdistan Region, Iraq.
  • Mohammad TAM; Hawler Medical University, College of Pharmacy, Department of Clinical Pharmacy, Erbil, Kurdistan Region, Iraq; Pharmacy department, School of Medicine, University of Kurdistan Hewlˆer (UKH), Erbil, Kurdistan Region, Iraq. Electronic address: Talar.m.mohammad1972@gmail.com.
  • Shawis TN; School of Medicine (Som), University of Kurdistan Hawler (UKH), Erbil, Kurdistan Region, Iraq.
Brain Res Bull ; 216: 111047, 2024 Oct 01.
Article en En | MEDLINE | ID: mdl-39128677
ABSTRACT

BACKGROUND:

Immune dysregulation can play a role in depression pathophysiology, and immunological antagonists can improve depressive symptoms in treatment-resistant bipolar depression (TRD) patients according to studies.

OBJECTIVE:

To evaluate the anti-depressant effects of the anti-inflammatory drug, pentoxifylline (PTX) in TRD bipolar I/II adult subjects.

METHODS:

This 12-week, randomized, double-blind, placebo-controlled, parallel-group trial of 60 participants was conducted at Hawler Psychiatric Hospital and Private Clinic in Erbil, Iraq. Participants were confirmed as being qualified for bipolar I/II depression based on DSM-5 criteria. Data were analyzed using modified intent-to-treat analysis.

RESULTS:

There were no significant differences between the two groups in Hamilton Rating Scale for Depression-17 (HAM-D-17) scores (χ2=1.9, P =.48) or a significant time × treatment interaction (χ2=7.1, P=.54). Nevertheless, a significant effect of time was observed with both groups' reduction in HAM-D-17 scores from the start to the endpoint (χ2= 2.11, P=.002). Besides, a significant time × treatment × CRP interaction was found (χ2=3.1, P=0.016), where there was more reduction in HAM-D-17 score in PTX-treated subjects with CRP> 7.1 mg/L. The response rate difference between PTX and the placebo group did not reach a significance level (χ2=0.84, p=0.43). Furthermore, serum concentrations of TNF-α, CRP, and IL-6 significantly reduced at week 12 in the PTX group (P=.007,.04, and <.001, respectively).

CONCLUSION:

The current proof of concept study found that in terms of overall anti-depressant effectiveness in bipolar patients with TRD, PTX is not superior to placebo. However, it may improve depressive mood in a subpopulation of subjects with a higher pretreatment inflammatory profile.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pentoxifilina / Trastorno Bipolar / Trastorno Depresivo Resistente al Tratamiento Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Res Bull Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pentoxifilina / Trastorno Bipolar / Trastorno Depresivo Resistente al Tratamiento Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Res Bull Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos